Bristol-Myers Squibb and Lilly enter clinical collaboration agreement to evaluate Opdivo (nivolumab) in combination with Galunisertib in advanced solid tumors
14 January 2015 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and Eli Lilly and Company announced a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) in combination with Lilly’s galunisertib (LY2157299)...